Search - tctmd.com

Displaying 61 - 80 of 174

Sort: Relevancy | Date

Presentation THT Abstracts 2025

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Presenter: Qianlan Xi

February 11, 2025

Presentation THT Abstracts 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT Abstracts 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

February 11, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Presenter: Arvind Kumar Venkataramana Raju

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation TCT 2024

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

Presenter: Bu-Yuan Hsiao

October 29, 2024

Presentation TCT 2024

TCT 132: Impact of Comorbid Heart Failure With Reduced Ejection Fraction (HFrEF) in the Development of Arrhythmias Among Patients Hospitalized for Transcatheter Aortic Valve Replacement (TAVR)

Presenter: Bruce Adrian Casipit

October 29, 2024

Presentation TCT 2024

TCT 468: No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes From Multi-Center Pilot Feasibility Studies

Presenter: Brian Potter

October 28, 2024

Advertisement

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

TCT 132: Impact of Comorbid Heart Failure With Reduced Ejection Fraction (HFrEF) in the Development of Arrhythmias Among Patients Hospitalized for Transcatheter Aortic Valve Replacement (TAVR)

TCT 468: No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes From Multi-Center Pilot Feasibility Studies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content